Estonia
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.53 (0.45 - 0.61) | 2019 | Modelled | IHME |
| 0.54 (0.46 - 0.62) | 2018 | Modelled | IHME |
| 0.55 (0.46 - 0.64) | 2017 | Modelled | IHME |
| 0.55 (0.47 - 0.64) | 2016 | Modelled | IHME |
| 0.56 (0.47 - 0.65) | 2015 | Modelled | IHME |
| 0.56 (0.49 - 0.64) | 2014 | Modelled | IHME |
| 0.57 (0.50 - 0.65) | 2013 | Modelled | IHME |
| 0.59 (0.51 - 0.67) | 2012 | Modelled | IHME |
| 0.6 (0.52 - 0.68) | 2011 | Modelled | IHME |
| 0.61 (0.52 - 0.70) | 2010 | Modelled | IHME |
| 0.62 (0.54 - 0.71) | 2009 | Modelled | IHME |
| 0.64 (0.55 - 0.72) | 2008 | Modelled | IHME |
| 0.65 (0.55 - 0.74) | 2007 | Modelled | IHME |
| 0.67 (0.56 - 0.76) | 2006 | Modelled | IHME |
| 0.68 (0.57 - 0.78) | 2005 | Modelled | IHME |
| 0.68 (0.58 - 0.79) | 2004 | Modelled | IHME |
| 0.69 (0.59 - 0.79) | 2003 | Modelled | IHME |
| 0.69 (0.59 - 0.80) | 2002 | Modelled | IHME |
| 0.7 (0.59 - 0.81) | 2001 | Modelled | IHME |
| 0.7 (0.60 - 0.82) | 2000 | Modelled | IHME |
| 0.71 (0.61 - 0.83) | 1999 | Modelled | IHME |
| 0.73 (0.62 - 0.84) | 1998 | Modelled | IHME |
| 0.74 (0.63 - 0.86) | 1997 | Modelled | IHME |
| 0.75 (0.64 - 0.87) | 1996 | Modelled | IHME |
| 0.75 (0.63 - 0.87) | 1995 | Modelled | IHME |
| 0.75 (0.63 - 0.86) | 1994 | Modelled | IHME |
| 0.75 (0.63 - 0.86) | 1993 | Modelled | IHME |
| 0.75 (0.62 - 0.86) | 1992 | Modelled | IHME |
| 0.74 (0.61 - 0.87) | 1991 | Modelled | IHME |
| 0.73 (0.59 - 0.87) | 1990 | Modelled | IHME |
| 0 (0 - 2) | 2013 | Survey/reported | Parke, 2017 |
| 1.12 (0.18 - 7.92) | 2015 | Modelled | WHO |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.03 (0.02 - 0.04) | 2019 | Modelled | IHME |
| 0.03 (0.02 - 0.04) | 2018 | Modelled | IHME |
| 0.03 (0.02 - 0.04) | 2017 | Modelled | IHME |
| 0.03 (0.02 - 0.04) | 2016 | Modelled | IHME |
| 0.03 (0.02 - 0.04) | 2015 | Modelled | IHME |
| 0.03 (0.02 - 0.04) | 2014 | Modelled | IHME |
| 0.03 (0.02 - 0.04) | 2013 | Modelled | IHME |
| 0.03 (0.02 - 0.04) | 2012 | Modelled | IHME |
| 0.03 (0.02 - 0.04) | 2011 | Modelled | IHME |
| 0.03 (0.02 - 0.04) | 2010 | Modelled | IHME |
| 0.03 (0.02 - 0.04) | 2009 | Modelled | IHME |
| 0.03 (0.02 - 0.04) | 2008 | Modelled | IHME |
| 0.04 (0.03 - 0.05) | 2007 | Modelled | IHME |
| 0.04 (0.03 - 0.05) | 2006 | Modelled | IHME |
| 0.05 (0.03 - 0.06) | 2005 | Modelled | IHME |
| 0.08 (0.06 - 0.11) | 2004 | Modelled | IHME |
| 0.14 (0.10 - 0.19) | 2003 | Modelled | IHME |
| 0.22 (0.16 - 0.30) | 2002 | Modelled | IHME |
| 0.3 (0.22 - 0.40) | 2001 | Modelled | IHME |
| 0.36 (0.26 - 0.48) | 2000 | Modelled | IHME |
| 0.41 (0.29 - 0.54) | 1999 | Modelled | IHME |
| 0.45 (0.32 - 0.60) | 1998 | Modelled | IHME |
| 0.49 (0.34 - 0.65) | 1997 | Modelled | IHME |
| 0.52 (0.36 - 0.69) | 1996 | Modelled | IHME |
| 0.53 (0.36 - 0.70) | 1995 | Modelled | IHME |
| 0.53 (0.37 - 0.69) | 1994 | Modelled | IHME |
| 0.52 (0.37 - 0.69) | 1993 | Modelled | IHME |
| 0.52 (0.36 - 0.69) | 1992 | Modelled | IHME |
| 0.51 (0.35 - 0.69) | 1991 | Modelled | IHME |
| 0.5 (0.34 - 0.69) | 1990 | Modelled | IHME |
| 0.36 (0.06 - 2.81) | 2015 | Modelled | WHO |
Showing out of
Show more
Men who have sex with men (MSM)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.03 (0 - 5.60) | 2015 | Survey/reported | K. R. Tervise Arengu Instituut, 2015. |
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 3.75 (2.63 - 5.28) | 2019 | Modelled | IHME |
| 3.81 (2.72 - 5.28) | 2018 | Modelled | IHME |
| 3.88 (2.89 - 5.28) | 2017 | Modelled | IHME |
| 3.99 (3.02 - 5.29) | 2016 | Modelled | IHME |
| 3.86 (2.91 - 5.09) | 2015 | Modelled | IHME |
| 3.99 (3.02 - 5.26) | 2014 | Modelled | IHME |
| 4.14 (3.17 - 5.42) | 2013 | Modelled | IHME |
| 4.64 (3.55 - 6.08) | 2012 | Modelled | IHME |
| 4.99 (3.80 - 6.50) | 2011 | Modelled | IHME |
| 5.14 (3.92 - 6.67) | 2010 | Modelled | IHME |
| 5.79 (4.40 - 7.50) | 2009 | Modelled | IHME |
| 6.41 (4.83 - 8.34) | 2008 | Modelled | IHME |
| 7.1 (5.35 - 9.17) | 2007 | Modelled | IHME |
| 6.94 (5.22 - 8.92) | 2006 | Modelled | IHME |
| 6.84 (5.18 - 8.74) | 2005 | Modelled | IHME |
| 6.79 (5.17 - 8.68) | 2004 | Modelled | IHME |
| 6.66 (5.11 - 8.52) | 2003 | Modelled | IHME |
| 6.7 (5.15 - 8.49) | 2002 | Modelled | IHME |
| 6.63 (5.08 - 8.41) | 2001 | Modelled | IHME |
| 6.02 (4.61 - 7.64) | 2000 | Modelled | IHME |
| 5.61 (4.37 - 7.05) | 1999 | Modelled | IHME |
| 5.55 (4.33 - 7) | 1998 | Modelled | IHME |
| 4.86 (3.78 - 6.18) | 1997 | Modelled | IHME |
| 4.38 (3.40 - 5.52) | 1996 | Modelled | IHME |
| 4.71 (3.65 - 5.99) | 1995 | Modelled | IHME |
| 4.52 (3.45 - 5.76) | 1994 | Modelled | IHME |
| 3.72 (2.86 - 4.72) | 1993 | Modelled | IHME |
| 3.08 (2.40 - 3.86) | 1992 | Modelled | IHME |
| 3 (2.33 - 3.78) | 1991 | Modelled | IHME |
| 2.78 (2.17 - 3.50) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 49 (35 - 69) | 2019 | Modelled | IHME |
| 50 (36 - 69) | 2018 | Modelled | IHME |
| 51 (38 - 69) | 2017 | Modelled | IHME |
| 52 (40 - 70) | 2016 | Modelled | IHME |
| 51 (38 - 67) | 2015 | Modelled | IHME |
| 53 (40 - 69) | 2014 | Modelled | IHME |
| 55 (42 - 72) | 2013 | Modelled | IHME |
| 61 (47 - 80) | 2012 | Modelled | IHME |
| 66 (51 - 86) | 2011 | Modelled | IHME |
| 69 (52 - 89) | 2010 | Modelled | IHME |
| 77 (59 - 100) | 2009 | Modelled | IHME |
| 86 (65 - 112) | 2008 | Modelled | IHME |
| 95 (72 - 123) | 2007 | Modelled | IHME |
| 94 (71 - 121) | 2006 | Modelled | IHME |
| 93 (70 - 119) | 2005 | Modelled | IHME |
| 93 (71 - 119) | 2004 | Modelled | IHME |
| 92 (70 - 117) | 2003 | Modelled | IHME |
| 93 (71 - 117) | 2002 | Modelled | IHME |
| 92 (71 - 117) | 2001 | Modelled | IHME |
| 84 (64 - 106) | 2000 | Modelled | IHME |
| 78 (61 - 99) | 1999 | Modelled | IHME |
| 78 (61 - 98) | 1998 | Modelled | IHME |
| 69 (53 - 87) | 1997 | Modelled | IHME |
| 63 (49 - 79) | 1996 | Modelled | IHME |
| 68 (53 - 87) | 1995 | Modelled | IHME |
| 67 (51 - 85) | 1994 | Modelled | IHME |
| 56 (43 - 71) | 1993 | Modelled | IHME |
| 48 (37 - 60) | 1992 | Modelled | IHME |
| 47 (36 - 59) | 1991 | Modelled | IHME |
| 44 (34 - 55) | 1990 | Modelled | IHME |
| 53 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 17 (12 - 23) | 2019 | Modelled | IHME |
| 17 (12 - 23) | 2018 | Modelled | IHME |
| 17 (12 - 24) | 2017 | Modelled | IHME |
| 17 (12 - 24) | 2016 | Modelled | IHME |
| 17 (12 - 24) | 2015 | Modelled | IHME |
| 17 (12 - 24) | 2014 | Modelled | IHME |
| 17 (12 - 24) | 2013 | Modelled | IHME |
| 18 (12 - 25) | 2012 | Modelled | IHME |
| 18 (13 - 25) | 2011 | Modelled | IHME |
| 18 (13 - 25) | 2010 | Modelled | IHME |
| 19 (13 - 26) | 2009 | Modelled | IHME |
| 19 (13 - 26) | 2008 | Modelled | IHME |
| 19 (14 - 27) | 2007 | Modelled | IHME |
| 20 (14 - 28) | 2006 | Modelled | IHME |
| 20 (14 - 28) | 2005 | Modelled | IHME |
| 21 (14 - 28) | 2004 | Modelled | IHME |
| 21 (15 - 29) | 2003 | Modelled | IHME |
| 22 (15 - 30) | 2002 | Modelled | IHME |
| 22 (16 - 31) | 2001 | Modelled | IHME |
| 22 (16 - 31) | 2000 | Modelled | IHME |
| 23 (16 - 31) | 1999 | Modelled | IHME |
| 23 (17 - 32) | 1998 | Modelled | IHME |
| 24 (17 - 32) | 1997 | Modelled | IHME |
| 24 (17 - 33) | 1996 | Modelled | IHME |
| 25 (18 - 33) | 1995 | Modelled | IHME |
| 25 (18 - 34) | 1994 | Modelled | IHME |
| 24 (18 - 33) | 1993 | Modelled | IHME |
| 24 (17 - 32) | 1992 | Modelled | IHME |
| 24 (17 - 32) | 1991 | Modelled | IHME |
| 24 (17 - 32) | 1990 | Modelled | IHME |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 93 | 2018 | Survey/reported | WHO/UNICEF |
| 92 | 2017 | Survey/reported | WHO/UNICEF |
| 93 | 2016 | Survey/reported | WHO/UNICEF |
| 91 | 2015 | Survey/reported | WHO/UNICEF |
| 93 | 2014 | Survey/reported | WHO/UNICEF |
| 93 | 2013 | Survey/reported | WHO/UNICEF |
| 94 | 2012 | Survey/reported | WHO/UNICEF |
| 94 | 2011 | Survey/reported | WHO/UNICEF |
| 94 | 2010 | Survey/reported | WHO/UNICEF |
| 95 | 2009 | Survey/reported | WHO/UNICEF |
| 94 | 2008 | Survey/reported | WHO/UNICEF |
| 95 | 2007 | Survey/reported | WHO/UNICEF |
| 95 | 2006 | Survey/reported | WHO/UNICEF |
| 95 | 2005 | Survey/reported | WHO/UNICEF |
| 90 | 2004 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 232 | 2017 | Survey/reported | EMCDDA, 2019 |
| 249 (135 - 339) | 2016 | Survey/reported | Estonia National Institute for Health Development, 2016. |
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2003
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 2.05 (1.67 - 2.51) | 2019 | Modelled | IHME |
| 2.05 (1.69 - 2.51) | 2018 | Modelled | IHME |
| 2.04 (1.68 - 2.50) | 2017 | Modelled | IHME |
| 2.03 (1.67 - 2.47) | 2016 | Modelled | IHME |
| 2.01 (1.63 - 2.47) | 2015 | Modelled | IHME |
| 2.02 (1.65 - 2.46) | 2014 | Modelled | IHME |
| 2.03 (1.65 - 2.47) | 2013 | Modelled | IHME |
| 2.05 (1.67 - 2.48) | 2012 | Modelled | IHME |
| 2.06 (1.67 - 2.49) | 2011 | Modelled | IHME |
| 2.06 (1.67 - 2.50) | 2010 | Modelled | IHME |
| 2.06 (1.66 - 2.50) | 2009 | Modelled | IHME |
| 2.06 (1.67 - 2.50) | 2008 | Modelled | IHME |
| 2.05 (1.67 - 2.49) | 2007 | Modelled | IHME |
| 2.05 (1.66 - 2.48) | 2006 | Modelled | IHME |
| 2.04 (1.65 - 2.49) | 2005 | Modelled | IHME |
| 2.03 (1.65 - 2.47) | 2004 | Modelled | IHME |
| 2.02 (1.64 - 2.47) | 2003 | Modelled | IHME |
| 2 (1.63 - 2.44) | 2002 | Modelled | IHME |
| 1.98 (1.61 - 2.44) | 2001 | Modelled | IHME |
| 1.97 (1.59 - 2.43) | 2000 | Modelled | IHME |
| 1.95 (1.59 - 2.39) | 1999 | Modelled | IHME |
| 1.93 (1.58 - 2.37) | 1998 | Modelled | IHME |
| 1.91 (1.56 - 2.35) | 1997 | Modelled | IHME |
| 1.89 (1.54 - 2.33) | 1996 | Modelled | IHME |
| 1.87 (1.52 - 2.31) | 1995 | Modelled | IHME |
| 1.86 (1.51 - 2.29) | 1994 | Modelled | IHME |
| 1.85 (1.50 - 2.27) | 1993 | Modelled | IHME |
| 1.83 (1.49 - 2.26) | 1992 | Modelled | IHME |
| 1.82 (1.48 - 2.24) | 1991 | Modelled | IHME |
| 1.81 (1.45 - 2.25) | 1990 | Modelled | IHME |
Showing out of
Show more
Prevalence of anti-HCV
Men who have sex with men (MSM)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.8 (0.20 - 6.20) | 2015 | Survey/reported | K. R. Tervise Arengu Instituut, 201 |
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 79.2 (67.40 - 91) | 2014 | Modelled | Degenhardt L et al, 2017 |
HCV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 5.68 (3.97 - 8) | 2019 | Modelled | IHME |
| 5.73 (4.13 - 7.83) | 2018 | Modelled | IHME |
| 5.81 (4.40 - 7.64) | 2017 | Modelled | IHME |
| 5.95 (4.57 - 7.65) | 2016 | Modelled | IHME |
| 5.7 (4.40 - 7.41) | 2015 | Modelled | IHME |
| 5.64 (4.32 - 7.38) | 2014 | Modelled | IHME |
| 5.36 (4.13 - 6.93) | 2013 | Modelled | IHME |
| 5.35 (4.12 - 6.95) | 2012 | Modelled | IHME |
| 5.25 (4.06 - 6.81) | 2011 | Modelled | IHME |
| 5.08 (3.90 - 6.54) | 2010 | Modelled | IHME |
| 5.41 (4.16 - 7.05) | 2009 | Modelled | IHME |
| 5.72 (4.43 - 7.48) | 2008 | Modelled | IHME |
| 6.05 (4.62 - 8) | 2007 | Modelled | IHME |
| 5.81 (4.46 - 7.61) | 2006 | Modelled | IHME |
| 5.69 (4.41 - 7.38) | 2005 | Modelled | IHME |
| 5.62 (4.32 - 7.32) | 2004 | Modelled | IHME |
| 5.53 (4.28 - 7.18) | 2003 | Modelled | IHME |
| 5.53 (4.30 - 7.22) | 2002 | Modelled | IHME |
| 5.47 (4.21 - 7.12) | 2001 | Modelled | IHME |
| 5.01 (3.89 - 6.47) | 2000 | Modelled | IHME |
| 4.68 (3.65 - 6.03) | 1999 | Modelled | IHME |
| 4.58 (3.59 - 5.96) | 1998 | Modelled | IHME |
| 4.04 (3.16 - 5.18) | 1997 | Modelled | IHME |
| 3.63 (2.81 - 4.62) | 1996 | Modelled | IHME |
| 3.82 (2.98 - 4.96) | 1995 | Modelled | IHME |
| 3.65 (2.79 - 4.74) | 1994 | Modelled | IHME |
| 3.02 (2.34 - 3.90) | 1993 | Modelled | IHME |
| 2.54 (1.97 - 3.23) | 1992 | Modelled | IHME |
| 2.46 (1.92 - 3.17) | 1991 | Modelled | IHME |
| 2.29 (1.78 - 2.95) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 75 (52 - 105) | 2019 | Modelled | IHME |
| 75 (54 - 103) | 2018 | Modelled | IHME |
| 76 (58 - 100) | 2017 | Modelled | IHME |
| 78 (60 - 101) | 2016 | Modelled | IHME |
| 75 (58 - 97) | 2015 | Modelled | IHME |
| 74 (57 - 97) | 2014 | Modelled | IHME |
| 71 (55 - 91) | 2013 | Modelled | IHME |
| 71 (55 - 92) | 2012 | Modelled | IHME |
| 70 (54 - 90) | 2011 | Modelled | IHME |
| 68 (52 - 87) | 2010 | Modelled | IHME |
| 72 (56 - 94) | 2009 | Modelled | IHME |
| 77 (59 - 100) | 2008 | Modelled | IHME |
| 81 (62 - 108) | 2007 | Modelled | IHME |
| 78 (60 - 103) | 2006 | Modelled | IHME |
| 77 (60 - 100) | 2005 | Modelled | IHME |
| 77 (59 - 100) | 2004 | Modelled | IHME |
| 76 (59 - 99) | 2003 | Modelled | IHME |
| 77 (59 - 100) | 2002 | Modelled | IHME |
| 76 (59 - 99) | 2001 | Modelled | IHME |
| 70 (54 - 90) | 2000 | Modelled | IHME |
| 65 (51 - 84) | 1999 | Modelled | IHME |
| 64 (50 - 84) | 1998 | Modelled | IHME |
| 57 (45 - 73) | 1997 | Modelled | IHME |
| 52 (40 - 66) | 1996 | Modelled | IHME |
| 56 (43 - 72) | 1995 | Modelled | IHME |
| 54 (41 - 70) | 1994 | Modelled | IHME |
| 46 (35 - 59) | 1993 | Modelled | IHME |
| 39 (30 - 50) | 1992 | Modelled | IHME |
| 38 (30 - 49) | 1991 | Modelled | IHME |
| 36 (28 - 46) | 1990 | Modelled | IHME |
| 107 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 28 (20 - 36) | 2019 | Modelled | IHME |
| 27 (20 - 36) | 2018 | Modelled | IHME |
| 28 (20 - 36) | 2017 | Modelled | IHME |
| 27 (20 - 35) | 2016 | Modelled | IHME |
| 27 (19 - 35) | 2015 | Modelled | IHME |
| 27 (19 - 35) | 2014 | Modelled | IHME |
| 27 (19 - 35) | 2013 | Modelled | IHME |
| 27 (19 - 35) | 2012 | Modelled | IHME |
| 27 (19 - 35) | 2011 | Modelled | IHME |
| 27 (19 - 35) | 2010 | Modelled | IHME |
| 27 (19 - 35) | 2009 | Modelled | IHME |
| 26 (19 - 35) | 2008 | Modelled | IHME |
| 26 (19 - 35) | 2007 | Modelled | IHME |
| 27 (19 - 35) | 2006 | Modelled | IHME |
| 27 (19 - 35) | 2005 | Modelled | IHME |
| 27 (19 - 35) | 2004 | Modelled | IHME |
| 27 (19 - 36) | 2003 | Modelled | IHME |
| 27 (19 - 35) | 2002 | Modelled | IHME |
| 27 (19 - 36) | 2001 | Modelled | IHME |
| 27 (20 - 36) | 2000 | Modelled | IHME |
| 27 (20 - 36) | 1999 | Modelled | IHME |
| 27 (20 - 36) | 1998 | Modelled | IHME |
| 27 (20 - 36) | 1997 | Modelled | IHME |
| 28 (20 - 36) | 1996 | Modelled | IHME |
| 27 (19 - 35) | 1995 | Modelled | IHME |
| 27 (19 - 35) | 1994 | Modelled | IHME |
| 27 (20 - 36) | 1993 | Modelled | IHME |
| 28 (20 - 36) | 1992 | Modelled | IHME |
| 28 (20 - 36) | 1991 | Modelled | IHME |
| 28 (20 - 37) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 300 | 2017 | Survey/reported | EMCDDA, 2019 |
| 249 (135 - 339) | 2016 | Survey/reported | Estonia National Institute for Health Development, 2016. |
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2003
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
HBV (HBsAg+)
0.53
(%)
2019
(0.45 - 0.61(%))
IHME
HCV (RNA/cAg+)
2.05
(%)
2019
(1.67 - 2.51(%))
IHME
Survey/surveillance
HBV (HBsAg+)
0
(%)
2013
(0 - 2(%))
Parke, 2017
HCV (anti-HCV)
0
(%)
2013
(0 - 2(%))
Parker, 2018
Hepatitis related deaths (national)
Modelled
HBV
49
2019
(35 - 69)
IHME
Survey/surveillance
No data available
HBV chart
Modelled
HCV
75
2019
(52 - 105)
IHME
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.03
(%)
2019, latest modelled
(0.02 - 0.04(%))
IHME
Prevalence PWID
HCV
79.20
(%)
2014, latest modelled
(67.40 - 91(%))
Degenhardt L et al, 2017
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
No. of syringes/PWID/year
Survey/surveillance
HCV
232
2017
EMCDDA, 2019
Eligible for HBV generic medicines
Eligible for HCV generic medicines